Cresco Labs Marks Historic Step Forward with Medical Cannabis Facility DEA Registration

CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today announced that it registered certain state-licensed medical cannabis facilities with the U.S. Drug Enforcement Administration (“DEA”) following the federal rescheduling of medical cannabis to Schedule III under the Controlled Substances.